1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Social Prescription Grants is sponsored by Mass Cultural Council. These grants support Community Health Centers that work primarily with patients utilizing MassHealth to implement arts prescriptions as a component of patient treatment plans, with the goal of advancing the role of arts and culture as a preventative factor for mental health and …
Get alerted about grants like this
Save a search for “Mass Cultural Council” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Social Prescription – Mass Cultural Council Our Vision for Communities List of Staff Assignments by Municipality Resources for Municipalities Rural Municipalities Toolkit Local Cultural Council Program LCC Grant Recipient Provisions Guidelines, Templates & Forms Tribal Cultural Council Program Designated Cultural Districts Cultural District Investment Grants Building Knowledge – Audience Data Collection Building Knowledge – Audience Engagement Conduct a Marketing Experiment Read the history of the CultureRx: Social Prescription Pilot (below).
Check out the press release: Introducing the First Statewide Social Prescribing Solution in the U.S. Download Arts on Prescription: A Field Guide for US Communities . Join the Social Prescription Initiative, by contacting Art Pharmacy . Brief History of the CultureRx: Social Prescription Pilot Whereas the practice of social prescription is common in other countries, Massachusetts was first to lead the practice here in the United States.
In January 2020, Mass Cultural Council launched Phase I of the pilot by choosing eight cultural organizations interested in participating in a Social Prescription Pilot Program designed to positively affect the health and well-being of the people of Massachusetts and the fiscal health of our nonprofit cultural organizations.
Our intention was to further develop cross-sector partnerships, demonstrate the protective and therapeutic effect of cultural and arts participation, and to create a model where the services provided by cultural organizations are funded. Through the four phases of the pilot, over 1940 prescriptions were issued .
Phase II, ran from July 1, 2020 to June 30, 2021 and expanded the program across the state to a broader cohort of 12 organizational grantees who had existing partnerships with professional care providers. The Phase II cohort of cultural organizations represented a diverse set of disciplines and modes of delivering service that needed to adjust to the ever-changing nature of COVID-19.
Although much of the work in both Phase I, II, and III had to be paused during the pandemic, requiring a much slower development of relationships, processes, trust needed in social prescription, many organizations were able to pivot to virtual and outdoor programming and find other inventive ways to connect with their communities.
Along with adapting programming, many developed sustainable practices, deepened their investment in DEIA, expanded their partnerships, and found ways to utilize time in the pandemic to create innovative methods and materials for recruitment.
We further developed cross-sector partnerships, including a national cohort of researchers, arts agencies, health practitioners, and cultural directors, and teaching artists to better understand and promote protective and therapeutic effects of cultural and arts participation.
In Phase III and IV (FY22 and FY23), we were aided by a Social Prescription Task Force and we were able to hire Dr. Tasha Golden as a Social Prescription Consultant.
Not only did she help organizations document and communicate impact, she also created multiple trainings for the Social Prescription cohort (in trauma-informed care, creating cross-sector partnerships, and in evaluation) but she also orchestrated a partnership with University of Florida, Arts and Medicine to co-create a practical, free, how-to resource guide Arts on Prescription: A Field Guide for US Communities (PDF).
In Phase IV consultant Amy Bantham (CEO/Founder of Move to Live®More ) was hired to find an entity who had a workable model for improving public and personal health with access cultural activities and experiences and could possibly scale social prescription in Massachusetts. Art Pharmacy was chosen for its proven model where the services and health impacts provided by cultural organizations can be sustainably and equitably funded.
Since 2021 they have supported art and culture prescriptions and will continue to expand to New York, Massachusetts, and California. In Phase V (FY24 and FY25), we released the Arts on Prescription: A Field Guide for US Communities (PDF) and launched the First Statewide Social Prescribing Solution in the U.S. (See also The Power of Arts in Whole-Person Health: Social Prescribing in Massachusetts from Mass General Brigham.)
Mass Cultural Council contracted with Art Pharmacy , a healthcare services business specializing in social prescribing, to implement, scale, and lead this work in Massachusetts. Art Pharmacy is now enrolling new arts and cultural organizations across the Commonwealth.
They also are enrolling new healthcare partners who can refer their patients to their services to improve mental health, address loneliness, and support chronic disease management. Art Pharmacy works within the same payment structures and models of care of other health services, but importantly their model is designed to be no-cost to patients.
Arts and cultural organizations : If you interested in learning more about joining Art Pharmacy’s network and receiving Art Pharmacy’s members at your organization, please reach out to Art Pharmacy . Healthcare payers and providers: If you are interested in learning more about partnering with Art Pharmacy to provide social prescribing services to your members/patients, please reach out to Art Pharmacy’s CEO Chris Appleton .
In FY20 and FY21, Mass Cultural Council reimbursed cultural organizations services they provided for the social prescriptions they fulfilled. In FY22 and FY23, Mass Cultural Council changed the structure so that each participating organization received an upfront grant of $10,000 per year to be used for all expenses related to Social Prescription activities that took place between each fiscal year.
In FY24 and FY25 (2023-2025) Mass Cultural Council engaged Art Pharmacy Phase V – FY24 and FY25 (2023-2025) Guided by the recommendations of 2022, and under the leadership and orchestration of Dr. Tasha Golden (International Arts and Mind lab at Johns Hopkins Medicine), our Task Force worked with Dr. Jill Sonke (and her team from the EpiArts Lab at UF Center for Arts in Medicine) to complete a Field Guide as a roadmap for developing “Arts on Prescription” programs throughout the nation.
By bridging the arts, healthcare, and public health sectors, the Field Guide addresses how together we can: 1. Elevate Whole-Person Care 2. Address Social Drivers of Health 3.
Strengthen Cross-sector Connections In Phase V – To scale Arts on Prescription we have transferred our learnings to Art Pharmacy who is successfully onboarding insurers, managed care providers and employers. They work with health plans/systems, community clinics, and other healthcare partners to enable healthcare providers to prescribe arts and culture to patients for both mental and physical health benefits.
Their model is being adopted by third-party payers, which is an important element of scaling this kind of care. Boston Globe, Mass Cultural Council and Art Pharmacy launch program to prescribe arts and culture for mental health (6/28/24) Boston Business Journal, Doctor says, visit a museum: A new push for ‘social prescribing’ in Mass.
(6/28/24) WBUR, starts country’s first arts prescription program for physical and behavioral health (7/5/24) The Culture Show, GBH News, Art prescriptions, Shark Week, and Pedro Alonzo (7/9/24) WCVB Channel 5, What is ‘Social Prescribing’? Program takes new approach to physical, mental health (7/11/24) The Bay State Banner, Take two arts activities and call me in the morning: Mass.
doctors can now prescribe arts for health concerns (8/1/24) PBS Next Avenue article, For Lonely Older Adults, a Social Prescription Is a Wonder Drug (11/13/24) Phase IV – FY23 (2022-2023) In Phase IV, 10 of the 12 organizations from Phase III continued to offer cultural activities from over 30 prescribers. Over 1,200 prescriptions were issued and redeemed.
Three Lenses on CultureRx: Social Prescription (9/7/23) New Round of Investments Made in Social Prescription CultureRx (12/6/22) The Trust Transfer Project and CultureRx: Social Prescription (11/1/22) Phase III – FY22 (2021-2022) In Phase III, we did not accept applications from other organizations but offered and received applications from the 12 programs wishing to recommit.
Focusing on creating and deepening a learning community to identify systemic barriers and create effective practices that promote active participation in social prescription, we formed a Social Prescription Task Force and continued to partner with the broad arts and health ecosystem to inform and enhance the work.
Our goals were to: Support cross sector partnerships and Remove barriers for community participation Cultivate knowledge and advocacy through research and evaluation.
Report: Mass Cultural Council’s “CultureRx” Evaluation of a Social Prescription Pilot (6/16/22) Time magazine article: Why Some Doctors Are Prescribing Ballroom Dance or a Day at the Museum (6/15/2022) Study Unveils Benefits & Recommendations for Social Prescription (6/16/22) Phase II – FY21 (2020-2021) In Phase II, the pilot expanded the program to include 12 organizations as we extended our capacity to offer the first statewide social prescription pilot in the United States.
We expanded our provider list to include doctors, social workers, community health workers, therapists, and teachers, with prescriptions generated to help connect clients with cultural experiences.
Social Prescription Pilot Explores Positive Health Impacts of Cultural Experiences for People & Communities (12/8/21) Introducing the FY21 CultureRx Social Prescription Pilot Cohort (10/26/20) Phase I – FY20 (2019-2020) Phase I was launched with eight organizations working with two professional care providers in Western Massachusetts, Caring Health Center in Springfield and MACONY Pediatrics in Berkshire County.
Running from January – June 30, 2020, this first phase focused on building a cohort of cultural organizations working with professional care providers to positively affect the health and well-being of the people of their community.
Report: 2020 Mass Cultural Council CultureRx Report Findings from the Berkshires & Springfield Findings from CultureRx Social Prescription Pilot (8/28/20) Social Prescription Pilot Program Phase I Findings (8/28/20) Podcast episode with a Doctor and RN: Prescribing Cultural Engagement as a Protective, Healthy Habit (8/14/20) Unveiling CultureRx at the State House (3/9/20) Introducing Our Social Prescription Pilot (2/21/20) Anita Walker betting culture is good for your health (1/21/20) Introducing the CultureRx Initiative (10/10/19) Planning – FY19 (2018-2019) Prescription: A Dose of Dance (3/26/2019) Social Prescription Research & Resources
Based on current listing details, eligibility includes: Community Health Centers that work primarily with patients utilizing MassHealth. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $25,000 (FY26 examples) Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
The Framingham Cultural Council Local Cultural Council Program is a grant from Mass Cultural Council (via Framingham Cultural Council) that funds arts, culture, and humanities projects benefiting the Framingham, Massachusetts community. As a local cultural council under the statewide Mass Cultural Council, the Framingham Cultural Council distributes grants of $300 to $1,500 to support locally meaningful programming and creative projects. Eligible applicants include nonprofits, schools, individual artists, and community groups based in Framingham, MA. Applications must be submitted between September 1 and October 17 for projects requiring funding in the following calendar year. The deadline for the current cycle is October 16, 2026.
The Framingham Cultural Council Local Cultural Council Program is a grant from Mass Cultural Council (via Framingham Cultural Council) that funds community arts, educational, and cultural activities in Framingham, Massachusetts. The program operates as a local cultural council under the statewide Mass Cultural Council, supporting projects that enrich local arts and culture. Eligible applicants include nonprofits, schools, artists, and community groups based in Framingham. Awards typically range from $300 to $1,500. Applications are accepted annually from September 1 through October 16 for projects needing funding the following calendar year.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.